U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794086) titled 'SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases' on Jan. 20.
Brief Summary: To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing high-level evidence-based medical evidence for the use of SBRT combined with PD-1 inhibitors in the treatment of unresectable colorectal cancer liver metastasis.
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Liver Metastases
Intervention:
RADIATION: Stereotactic body...